

Clinical trials of chemotherapy for lung cancer (metastatic) in all type of patients

TrialResults-center www.trialresultscenter.org

1 pemetrexed alone

Trial	Treatments	Patients	Trials design and methods
pemetrexed vs bortezomib			
Scagliotti (pemetrexed vs bortezomib) , 2010 n=NA	pemetrexed versus bortezomib	-	
pemetrexed vs docetaxel			
Chen , 2008 n=34/33	-	-	
Hanna , 2004 n=283/288 follow-up:	pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with vitamin B(12), folic acid, and dexamethasone versus docetaxel 75 mg/m(2) i.v. day 1 with dexamethasone every 21 days	patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy	
Li , 2012 n=132/128 follow-up:	pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone versus docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone	patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks	
Sun , 2013 [NCT00391274] n=107/104 follow-up:	pemetrexed (500 mg/m(2); on Day 1 of each 21-day cycle versus docetaxel (75 mg/m(2) on Day 1 of each 21-day cycle	second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer	open-label

References

Scagliotti (pemetrexed vs bortezomib), 2010:

Scagliotti GV, Germonpr P, Bosque L, Vansteenkiste J, Gervais R, Planchard D, Reck M, De Marinis F, Lee JS, Park K, Biesma B, Gans S, Ramlau R, Szczesna A, Makhson A, Manikhas G, Morgan B, Zhu Y, Chan KC, von Pawel J A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. *Lung Cancer* 2010;68:420-6 [[19692142](#)] [10.1016/j.lungcan.2009.07.011](https://doi.org/10.1016/j.lungcan.2009.07.011)

Chen, 2008:

Hanna, 2004:

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol* 2004;22:1589-97 [[15117980](#)] [10.1200/JCO.2004.08.163](https://doi.org/10.1200/JCO.2004.08.163)

Li, 2012:

Li R, Sun L, Wang J, Qian J, Wang Z, Jiao X Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. *Pulm Pharmacol Ther* 2012;25:364-70 [22766314] [10.1016/j.pupt.2012.06.008](https://doi.org/10.1016/j.pupt.2012.06.008)

Sun, 2013:

Sun Y, Wu YL, Zhou CC, Zhang L, Zhang L, Liu XY, Yu SY, Jiang GL, Li K, Qin SK, Ma SL, Han L, Quinlivan M, Orlando M, Zhang XQ Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study. *Lung Cancer* 2013;79:143-50 [23182660] [10.1016/j.lungcan.2012.10.015](https://doi.org/10.1016/j.lungcan.2012.10.015)

2 pemetrexed doublet

Trial	Treatments	Patients	Trials design and methods
pemetrexed plus carboplatin vs docetaxel plus carboplatin			
Jose , 2011 n=106/105 follow-up:	carboplatin (area under the curve = 5 mg/ml min) and pemetrexed (500 mg/m(2)) 21-day cycle (maximum of six cycles). versus docetaxel (75 mg/m(2)).	first-line treatment for advanced, nonsquamous non-small cell lung cancer	
Socinski , 2010 n=74/72 follow-up:	pemetrexed 500 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to 6 cycles versus docetaxel 75 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to six cycles	Patients with stage IIIB (with pleural effusion) or IV non-small cell lung cancer and performance status 0 or 1	
bortezomib and pemetrexed vs pemetrexed			
Scagliotti , 2010 n=NA follow-up:	Pemetrexed plus Bortezomib versus pemetrexed	-	
enzastaurin plus pemetrexed vs pemetrexed			
Chiappori , 2010 n=NA follow-up:	Pemetrexed plus enzastaurin versus pemetrexed	-	
matuzumab plus pemetrexed vs pemetrexed			
Schiller , 2010 n=NA follow-up:	Pemetrexed plus matuzumab versus pemetrexed	-	
pemetrexed plus carboplatin vs pemetrexed			
Smit , 2009 n=NA	Pemetrexed plus carboplatin versus pemetrexed	-	
vandetanib plus pemetrexed vs pemetrexed			
De Boer , 2011 n=NA follow-up:	Vandetanib plus pemetrexed versus pemetrexed	-	

References

Jose, 2011:

Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martinez-Barrera L, Barraclough H, van Kooten M, Orlando M A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. *J Thorac Oncol* 2011;6:1907-14 [[22005471](#)] [10.1097/JTO.0b013e318226b5fa](#)

Socinski, 2010:

Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, Barrera D, Rousey SR, Choksi JK, Jotte R, Patt DA, Periman PO, Schlossberg HR, Weissman CH, Wang Y, Asmar L, Pritchard S, Bromund J, Peng G, Treat J, Obasaju CK Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. *J Thorac Oncol* 2010;5:1963-9 [[21102260](#)] [10.1097/JTO.0b013e3181fd42eb](#)

Scagliotti, 2010:

Scagliotti GV, Germonpr P, Bosque L, Vansteenkiste J, Gervais R, Planchard D, Reck M, De Marinis F, Lee JS, Park K, Biesma B, Gans S, Ramlau R, Szczesna A, Makhson A, Manikhas G, Morgan B, Zhu Y, Chan KC, von Pawel J A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. *Lung Cancer* 2010;68:420-6 [[19692142](#)] [10.1016/j.lungcan.2009.07.011](#)

Chiappori, 2010:

Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, Barata F, Scagliotti G, Park K, Wagle A, Liepa AM, Zhao YD, Chouaki N, Iscoe N, von Pawel J Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. *J Thorac Oncol* 2010;5:369-75 [[20090562](#)] [10.1097/JTO.0b013e3181ccee24f](#)

Schiller, 2010:

Schiller JH, von Pawel J, Schtt P, Ansari RH, Thomas M, Saleh M, McCroskey RD, Pfeifer W, Marsland TA, Kloecker GH, Sebastian M, Pirker R, Kurek R, Beadman C, Socinski MA Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. *J Thorac Oncol* 2010;5:1977-85 [[20978446](#)] [10.1097/JTO.0b013e3181f4a5c9](#)

Smit, 2009:

De Boer, 2011:

de Boer RH, Arrieta , Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. *J Clin Oncol* 2011;29:1067-74 [[21282537](#)] [10.1200/JCO.2010.29.5717](#)

Entry terms: vandetanib , caprelsa, ZD 6474, ZD6474, ZD-6474, vandetanib, Zactima,

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.